Nantkwest and immunitybio to initiate a phase 2 study of immunotherapy for metastatic pancreatic cancer

Nantkwest, inc. (nasdaq: nk), a clinical-stage, natural killer cell-based therapeutics company, and immunitybio, a privately-held immunotherapy compan

HCI Ratings Summary

HCI Quant Ranking